ACCEPTABILITY STUDY ON KETOGENIC DIET USING CAMBROOKE'S KETOVIE™

  • Research type

    Research Study

  • Full title

    ACCEPTABILITY STUDY ON KETOGENIC DIET SUPPLEMENT USING CAMBROOKE KETOVIE™ MEDICAL FOODS

  • IRAS ID

    228906

  • Contact name

    Victoria Whiteley

  • Contact email

    victoria.whiteley@mft.nhs.uk

  • Sponsor organisation

    Cambrooke Therapeutics

  • Duration of Study in the UK

    1 years, 0 months, 8 days

  • Research summary

    The objective of this study is to evaluate the acceptability, G.I. tolerance and palatability of Ketovie™ medical food for patients on ketogenic diet (KD).
    Persons with intractable epilepsy and other neurodegenerative disorders, such as glucose transporter type-1 deficiency syndrome (GLUT-1 DS) and pyruvate dehydrogenase deficiency (PDHD), who cannot rely on traditional drugs for their treatment may be treated with dietary therapy. KD is a high fat diet where carbohydrates are almost completely eliminated so that almost no glucose is available for the body to burn as energy. The diet can be difficult to follow and is very restrictive, because even the smallest amounts of carbohydrates will disrupt ketosis. As demonstrated by several studies, the KD therapy is an effective treatment is reducing the number of seizures in patients with intractable epilepsy and neurodegenerative disorders. .
    Ketovie is a convenient ready-to-drink, good-tasting, nutritionally complete option for the patient on KD. It has a 4:1 (four parts fat to 1 part combined protein and usable carbohydrates) formulation and it’s fortified with vitamins and minerals. Patients, currently on an oral KD and with one of several disorders: epilepsy, GLUT-1 DS, PDHD, or other disorders where a ketogenic diet is indicated, over 3 years of age, both male and female, will be given a choice of 2 flavors of Ketovie and asked to consume 1 per day for 7 days as a component of their KD therapy. The patient or their caregiver will record the quantity and time each Ketovie beverage is consumed and answer a series of questions regarding the daily experience (taste, smell, texture, ease of use, if any G.I disturbance.

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    18/WM/0312

  • Date of REC Opinion

    17 Dec 2018

  • REC opinion

    Further Information Favourable Opinion